Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update

Virax Biolabs Group Limited (NASDAQ:VRAX) was the recipient of a significant increase in short interest in May. As of May 29th, there was short interest totaling 1,068,991 shares, an increase of 173.2% from the May 14th total of 391,277 shares. Approximately 44.8% of the company’s stock are sold short. Based on an average daily trading volume, of 110,754,674 shares, the short-interest ratio is currently 0.0 days.

Virax Biolabs Group Trading Down 3.5%

Shares of VRAX stock traded down $0.01 on Friday, reaching $0.18. The company’s stock had a trading volume of 613,547 shares, compared to its average volume of 17,264,074. The stock’s fifty day simple moving average is $0.18 and its 200-day simple moving average is $0.26. Virax Biolabs Group has a 1 year low of $0.10 and a 1 year high of $1.14.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Virax Biolabs Group in a research note on Wednesday, April 8th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $1.00.

Virax Biolabs Group Company Profile

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.